Vaccine developer Bharat Biotech International Ltd is exploring to raise over $500 million through an initial public offering, according to a Bloomberg report citing people familiar with the matter. Founded in 1996, Bharat Biotech claimed to have distributed over 9 billion vaccines globally, the report said. Covid-19 vaccine Covaxin was indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology . Under the agreement, Bharat Biotech commits to producing and supplying MTBVAC to over 70 countries in Africa and Southeast Asia, areas significantly affected by the disease. Also Read | Shree Ram Twistex IPO: 10 key risks you should know about before investingAbout Bharat Biotech Headquartered in Genome Valley, Hyderabad, Bharat Biotech manufactures vaccines and biopharmaceuticals to combat infectious diseases.

Source: Mint February 27, 2026 18:33 UTC